Intra-Cellular Therapies (NASDAQ:ITCI) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI) in a report published on Saturday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also recently weighed in on ITCI. Piper Sandler reaffirmed a “neutral” rating and set a $132.00 price objective (up previously from $107.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, January 14th. Needham & Company LLC reaffirmed a “hold” rating and set a $100.00 price target on shares of Intra-Cellular Therapies in a report on Monday, January 13th. Cantor Fitzgerald raised shares of Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 14th. Royal Bank of Canada restated a “sector perform” rating and set a $132.00 target price (up from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Finally, Canaccord Genuity Group lowered Intra-Cellular Therapies from a “buy” rating to a “hold” rating and lifted their price target for the company from $119.00 to $132.00 in a research note on Friday, January 31st. Nine analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $103.62.

Intra-Cellular Therapies Price Performance

Shares of NASDAQ ITCI opened at $127.12 on Friday. The stock has a market capitalization of $13.52 billion, a PE ratio of -146.11 and a beta of 0.72. Intra-Cellular Therapies has a fifty-two week low of $62.78 and a fifty-two week high of $128.00. The business has a fifty day moving average price of $101.55 and a two-hundred day moving average price of $86.33.

Insider Transactions at Intra-Cellular Therapies

In other news, CEO Sharon Mates sold 51,000 shares of Intra-Cellular Therapies stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the transaction, the chief executive officer now owns 1,070,329 shares in the company, valued at approximately $91,834,228.20. The trade was a 4.55 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 2.60% of the company’s stock.

Institutional Trading of Intra-Cellular Therapies

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. True Wealth Design LLC bought a new stake in shares of Intra-Cellular Therapies in the 3rd quarter valued at about $32,000. GAMMA Investing LLC lifted its stake in shares of Intra-Cellular Therapies by 46.3% in the fourth quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock worth $63,000 after acquiring an additional 240 shares during the period. Capital Performance Advisors LLP bought a new stake in Intra-Cellular Therapies in the third quarter valued at approximately $74,000. Venturi Wealth Management LLC acquired a new stake in Intra-Cellular Therapies during the 4th quarter valued at approximately $96,000. Finally, Wilmington Savings Fund Society FSB bought a new position in Intra-Cellular Therapies during the 3rd quarter worth approximately $97,000. 92.33% of the stock is currently owned by institutional investors and hedge funds.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.